- Home
- NHIC vs XOMA Comparison
NHIC vs XOMA Comparison
Compare NHIC & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NHIC
- XOMA
- Stock Information
- Founded
- NHIC 2024
- XOMA 1981
- Country
- NHIC United States
- XOMA United States
- Employees
- NHIC N/A
- XOMA N/A
- Industry
- NHIC
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- NHIC
- XOMA Health Care
- Exchange
- NHIC NYSE
- XOMA Nasdaq
- Market Cap
- NHIC 275.3M
- XOMA 250.1M
- IPO Year
- NHIC 2025
- XOMA N/A
- Fundamental
- Price
- NHIC $9.99
- XOMA $24.32
- Analyst Decision
- NHIC
- XOMA Strong Buy
- Analyst Count
- NHIC 0
- XOMA 2
- Target Price
- NHIC N/A
- XOMA $69.50
- AVG Volume (30 Days)
- NHIC 24.8K
- XOMA 20.9K
- Earning Date
- NHIC 01-01-0001
- XOMA 05-12-2025
- Dividend Yield
- NHIC N/A
- XOMA N/A
- EPS Growth
- NHIC N/A
- XOMA N/A
- EPS
- NHIC N/A
- XOMA N/A
- Revenue
- NHIC N/A
- XOMA $28,487,000.00
- Revenue This Year
- NHIC N/A
- XOMA $17.89
- Revenue Next Year
- NHIC N/A
- XOMA $34.58
- P/E Ratio
- NHIC N/A
- XOMA N/A
- Revenue Growth
- NHIC N/A
- XOMA 498.72
- 52 Week Low
- NHIC $10.26
- XOMA $18.35
- 52 Week High
- NHIC $10.28
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- NHIC N/A
- XOMA 65.18
- Support Level
- NHIC N/A
- XOMA $22.79
- Resistance Level
- NHIC N/A
- XOMA $25.10
- Average True Range (ATR)
- NHIC 0.00
- XOMA 1.07
- MACD
- NHIC 0.00
- XOMA 0.31
- Stochastic Oscillator
- NHIC 0.00
- XOMA 84.71
About NHIC NEWHOLD INVESTMENT CORP III
NewHold Investment Corp III is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.